New hope for pancreatic cancer: novel drug combo enters final trial phase

NCT ID NCT06752811

Recruiting now Disease control Sponsor: Shanghai Yizhong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial is testing whether a new formulation of the chemotherapy drug paclitaxel, given with gemcitabine, works better than the current standard treatment for metastatic pancreatic cancer. The study will enroll 416 adults who have not yet received treatment for their advanced cancer. Researchers will measure how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: paclitaxel polymeric micelles plus gemcitabine
What this could lead to: If successful, this could offer a more effective first-line treatment option for metastatic pancreatic cancer, potentially improving survival and tumor control.
What could go wrong: This is a Phase 3 trial, but the new drug formulation may not prove superior to the existing standard. Side effects from chemotherapy remain significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER METASTATIC

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 201400, China
Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.